Mereo BioPharma Group (NASDAQ:MREO – Get Free Report)‘s stock had its “overweight” rating restated by equities research analysts at Cantor Fitzgerald in a research report issued on Thursday, Benzinga reports. They presently have a $7.00 target price on the stock. Cantor Fitzgerald’s price objective would suggest a potential upside of 113.41% from the company’s current […]
Mereo BioPharma Group plc (NASDAQ:MREO – Get Free Report) was the recipient of a significant decline in short interest in the month of July. As of July 31st, there was short interest totalling 6,200,000 shares, a decline of 19.5% from the July 15th total of 7,700,000 shares. Based on an average daily volume of 1,830,000 […]
Monaco Asset Management SAM grew its stake in shares of Mereo BioPharma Group plc (NASDAQ:MREO – Get Rating) by 998.1% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 2,049,661 shares of the company’s stock after acquiring an additional 1,863,005 shares during the quarter. Monaco […]